Clinical trial
Phase IIIb Study to Evaluate the Effectiveness and Safety of…
NCT00337467 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00337467 |
|---|---|
| Title | Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression |
| Official title | Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study |
| Acronym | OREY |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus (HIV) Infections |
| Intervention type | Drug |
| Interventions | Atazanavir + Ritonavir |
| Enrollment | 61 |
| Start date | Jun 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Jun 16, 2006 |
| Last update posted | Jul 19, 2010 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: